Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, et al. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol 2026;27:68-78.
PMID: 41449150